我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
8
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
3
37.5%
已完成
2
25.0%
招募中
终止
1
12.5%
暂无批准数据
- LeMaitre Vascular posted Q2 2026 sales of $70.4 million, a 10% organic increase, with Artegraft sales surging 34% to account for 21% of total revenue. - Gross margin expanded 210 basis points to 72.1%, while operating income rose 26% to a record $20.4 million, representing a 29% operating margin. - The company raised its 2026 Artegraft sales forecast to $11 million and now has regulatory approvals in 56 countries, with recent additions including Vietnam, Morocco, and Turkey. - Full-year 2026 guidance projects $276.3 million in revenue with 11% organic growth and EPS of $2.89, up 21% on an adjusted basis.
